↳ get_safety_profile result

show data

{
  "drug_class": "DLL3 T-cell engager",
  "class_effect_aes": [
    "Cytokine release syndrome (CRS) \u2014 common, mostly cycle-1, can be high-grade",
    "Immune effector cell-associated neurotoxicity syndrome (ICANS) / neurotoxicity",
    "Cytopenias (neutropenia, anemia, thrombocytopenia)",
    "Hypogammaglobulinemia / infection risk from on-target B/neuroendocrine effects",
    "Tumor flare / pyrexia"
  ],
  "monitoring": [
    "Inpatient monitoring for CRS during step-up/priming doses (cycle 1)",
    "Frequent vitals, ferritin/CRP trend during CRS window",
    "Baseline + on-treatment neuro exam (ICE score) for ICANS",
    "Baseline ECG/echo if cardiac reserve is a concern during CRS",
    "CBC with differential before each dose"
  ],
  "contraindicated_comorbidities": [
    "Active CNS metastases / leptomeningeal disease (raises ICANS danger)",
    "Active autoimmune CNS disease or seizure disorder",
    "Inadequate cardiac reserve (CRS hemodynamic stress) \u2014 recent MI, NYHA III/IV CHF",
    "Active uncontrolled infection (CRS masks/worsens sepsis)",
    "Significant baseline hypoxia / poor pulmonary reserve"
  ],
  "ddi_flags": [
    "Live vaccines contraindicated (immune activation)",
    "Chronic systemic immunosuppression / high-dose steroids blunt efficacy and confound CRS grading",
    "Tocilizumab/steroids must be available on-site as CRS rescue"
  ],
  "notes": "First-in-human TCEs need a step-up/priming dose schedule and mandated CRS/ICANS rescue medication on hand; cycle-1 inpatient observation is standard."
}

↳ get_precedent_criteria result

show data

{
  "indication": "ES-SCLC",
  "precedent_trials": [
    "Tarlatamab DeLLphi-301/304 (DLL3 TCE)",
    "IMpower133 (1L chemo-IO)"
  ],
  "inclusion": [
    "Histologically/cytologically confirmed extensive-stage SCLC",
    "Relapsed/refractory after >=1 prior platinum-based regimen (line per protocol)",
    "Measurable disease per RECIST v1.1",
    "ECOG performance status 0-1",
    "Adequate hematologic, hepatic, renal organ function (see lab thresholds)",
    "Life expectancy >=12 weeks"
  ],
  "exclusion": [
    "Untreated/active/symptomatic CNS metastases (treated, stable may be allowed)",
    "Leptomeningeal disease / carcinomatous meningitis",
    "Active autoimmune disease or condition needing systemic immunosuppression (for IO/TCE)",
    "Insufficient washout from prior anticancer therapy (e.g. ~3-4 wks or 5 half-lives)",
    "Uncontrolled intercurrent illness / active infection",
    "Second malignancy requiring active treatment"
  ],
  "notes": "DLL3 TCE precedents often allow treated/stable brain mets but exclude active CNS disease specifically because of ICANS/neurotoxicity risk."
}

↳ get_lab_thresholds result

show data

{
  "hematologic": [
    {
      "parameter": "Absolute neutrophil count (ANC)",
      "typical_threshold": ">= 1.5 x 10^9/L",
      "rationale": "Adequate marrow reserve before a myelosuppressive agent; lower (>=1.0) sometimes allowed if marrow involvement."
    },
    {
      "parameter": "Platelets",
      "typical_threshold": ">= 100 x 10^9/L (>=75 if marrow involvement)",
      "rationale": "Bleeding risk and tolerance of thrombocytopenia."
    },
    {
      "parameter": "Hemoglobin",
      "typical_threshold": ">= 9.0 g/dL (transfusion-independent)",
      "rationale": "Baseline reserve; many protocols require independence from recent transfusion."
    }
  ],
  "hepatic": [
    {
      "parameter": "Total bilirubin",
      "typical_threshold": "<= 1.5 x ULN (<=3 x ULN if Gilbert's/liver mets)",
      "rationale": "Hepatic clearance reserve; relaxed for documented Gilbert's or hepatic metastases."
    },
    {
      "parameter": "AST / ALT",
      "typical_threshold": "<= 3 x ULN (<=5 x ULN if liver metastases)",
      "rationale": "Baseline hepatocellular integrity; key for hepatotoxic agents (PI3Ki, JAKi)."
    },
    {
      "parameter": "Albumin",
      "typical_threshold": ">= 2.8-3.0 g/dL (some protocols)",
      "rationale": "Synthetic liver function / nutritional status, esp. GI cancers."
    }
  ],
  "renal": [
    {
      "parameter": "Creatinine clearance (Cockcroft-Gault)",
      "typical_threshold": ">= 50-60 mL/min",
      "rationale": "Renal elimination reserve; threshold depends on renal clearance of the drug."
    },
    {
      "parameter": "Serum creatinine",
      "typical_threshold": "<= 1.5 x ULN",
      "rationale": "Simpler surrogate when CrCl not used."
    }
  ],
  "cardiac": [
    {
      "parameter": "Left-ventricular ejection fraction (LVEF)",
      "typical_threshold": ">= 50% (institutional LLN)",
      "rationale": "Required for cardiotoxic agents (anti-HER2, anthracycline exposure)."
    },
    {
      "parameter": "QTc (Fridericia)",
      "typical_threshold": "<= 470 ms (women) / <= 450 ms (men)",
      "rationale": "Exclude baseline prolongation for QT-liable agents; pair with congenital long-QT exclusion."
    }
  ],
  "coagulation_metabolic": [
    {
      "parameter": "INR / aPTT (if on anticoagulation off-study)",
      "typical_threshold": "within therapeutic range / <= 1.5 x ULN",
      "rationale": "Bleeding risk, esp. for agents with hemorrhage signal (BTKi)."
    },
    {
      "parameter": "Fasting glucose / HbA1c",
      "typical_threshold": "HbA1c <= 6.5-8.0% per protocol",
      "rationale": "Baseline glycemic control for hyperglycemia-liable agents (PI3K-alpha)."
    }
  ],
  "notes": "Teaching-snapshot typical oncology cutoffs. Exact thresholds and relaxations (marrow involvement, liver mets, Gilbert's) are drug- and protocol-specific and must be set against the investigator's brochure and standard of care."
}

Agent · turn 2

Below is a Phase 1, first-in-human, dose-escalation/expansion trial eligibility framework for a DLL3 T‑cell engager (BiTE) in relapsed/refractory extensive-stage SCLC (ES‑SCLC). It is written to balance:

✅ Patient safety (CRS/ICANS, cytopenias, cardiopulmonary stress)
✅ Real-world enrollability in heavily pretreated ES‑SCLC
✅ Consistency with DLL3 TCE and IO precedents

Key Design Assumptions (Operational Context)

Step-up (priming) dosing in Cycle 1
Inpatient monitoring during initial doses
Tocilizumab and corticosteroids immediately available
Standard CRS/ICANS grading per ASTCT

Inclusion Criteria

1. Disease Characteristics

Histologically or cytologically confirmed small cell lung cancer.
Extensive-stage disease at study entry.
Relapsed or refractory after:
- ≥1 prior platinum-based regimen (must have received platinum/etoposide)
- Prior PD-1/PD-L1 therapy unless contraindicated or not available.
Measurable disease per RECIST v1.1.
Radiographic progression on or after most recent therapy.

2. Performance Status and Prognosis

ECOG performance status 0–1
(Consider allowing ECOG 2 in dose-expansion once safety is characterized.)
Estimated life expectancy ≥ 12 weeks.

3. Organ Function (within 7–14 days of first dose)

Hematologic

ANC ≥ 1.5 × 10⁹/L
(≥1.0 × 10⁹/L allowed if marrow involvement)
Platelets ≥ 100 × 10⁹/L
(≥75 × 10⁹/L if marrow involvement)
Hemoglobin ≥ 9.0 g/dL (transfusion allowed)

Hepatic

Total bilirubin ≤ 1.5 × ULN
(≤3 × ULN if Gilbert’s or liver metastases)
AST/ALT ≤ 3 × ULN
(≤5 × ULN if liver metastases)

Renal

Creatinine clearance ≥ 50 mL/min (Cockcroft-Gault)
OR serum creatinine ≤ 1.5 × ULN

4. CNS Disease (Balanced for Enrollability)

Treated brain metastases are allowed if:
- Definitively treated (radiation or surgery)
- Clinically stable ≥2 weeks
- Off steroids or on physiologic replacement only (≤10 mg prednisone equivalent)
Asymptomatic untreated brain metastases ≤2 cm may be allowed in dose-expansion only, provided:
- No mass effect
- No edema requiring steroids

(Important for enrollability in ES-SCLC while mitigating ICANS risk.)

5. CRS/ICANS Safety-Specific Inclusion

Baseline neurologic exam without clinically significant deficits.
No history of grade ≥3 immune-related neurologic toxicity from prior IO.
Oxygen saturation ≥ 92% on room air.
Adequate cardiac reserve:
- No symptomatic heart failure
- No MI within 6 months
- No unstable arrhythmias

6. Washout Periods

≥2 weeks from prior chemotherapy or radiation (≥4 weeks for nitrosoureas/mitomycin C).
≥4 weeks from prior investigational biologic agents.
Toxicities from prior therapy recovered to Grade ≤1 (except alopecia, stable neuropathy ≤Grade 2).

Exclusion Criteria

1. CNS / Neurologic Risk (ICANS Mitigation)

Active, untreated, or symptomatic brain metastases.
Leptomeningeal disease.
History of:
- Seizure disorder requiring anti-epileptics
- Stroke within 6 months
- Clinically significant CNS hemorrhage
Active autoimmune neurologic disease (e.g., MS, myasthenia gravis).
Baseline ≥ Grade 2 cognitive impairment.

2. CRS Risk Amplifiers

Active uncontrolled infection (including sepsis).
Known active hepatitis B, C with viremia.
HIV with detectable viral load.
Ongoing systemic immunosuppression:
- >10 mg prednisone equivalent daily within 7 days of first dose.
Active autoimmune disease requiring systemic therapy within past 2 years (replacement therapy allowed).

3. Cardiopulmonary Risk (CRS Hemodynamic Stress)

NYHA Class III or IV heart failure.
LVEF < 45–50% (if clinically indicated to assess).
Clinically significant pericardial effusion.
Baseline QTcF > 470 ms.
Significant baseline hypoxia requiring >2L supplemental O₂.
Uncontrolled COPD exacerbation or active pneumonitis.

4. Hematologic / Organ Exclusions

Platelets < 75 × 10⁹/L.
ANC < 1.0 × 10⁹/L.
AST/ALT > 5 × ULN without liver metastases.
Creatinine clearance < 40 mL/min.

5. Other Standard Exclusions

Second active malignancy requiring treatment.
Major surgery within 2 weeks.
Pregnancy or breastfeeding.
Live vaccines within 4 weeks.

Optional Risk Mitigation Measures (Protocol-Specified, Not Eligibility)

To further balance safety and enrollability without over-restricting:

Mandatory inpatient monitoring for:
Cycle 1 Day 1 and step-up doses
Baseline and serial ICE scoring
Baseline CRP and ferritin
Tocilizumab available within 2 hours
Pre-medication (e.g., dexamethasone) during priming doses
Exclude first-patient-in-human cohort from patients with:
Brain metastases
ECOG 2
Heavy tumor burden causing baseline hypoxia

Rationale for Key Decisions

Risk	Design Approach	Enrollability Impact
CRS	Exclude unstable cardiac/pulmonary disease; allow stable comorbidities	Preserves real-world population
ICANS	Allow treated/stable brain mets	Critical for ES-SCLC feasibility
Cytopenias	Allow marrow involvement with lower thresholds	Prevents over-exclusion
Steroids	Allow physiologic replacement	Avoids unnecessary exclusions
ECOG	0–1 initially	Expand to 2 once safety established

Optional Expansion Cohort Relaxations (After Dose Escalation)

Once RP2D safety is defined:
- Allow ECOG 2
- Allow asymptomatic untreated brain mets
- Lower ANC threshold to 1.0 × 10⁹/L universally
- Broaden CrCl to ≥40 mL/min

If helpful, I can next provide:

A Dose-Limiting Toxicity (DLT) definition framework tailored to CRS/ICANS,
A Cycle 1 hospitalization and monitoring schema, or
A risk-adapted eligibility strategy comparing “conservative FIH” vs “competitive landscape” approaches.

Final output

✅ Patient safety (CRS/ICANS, cytopenias, cardiopulmonary stress)
✅ Real-world enrollability in heavily pretreated ES‑SCLC
✅ Consistency with DLL3 TCE and IO precedents

Key Design Assumptions (Operational Context)

Step-up (priming) dosing in Cycle 1
Inpatient monitoring during initial doses
Tocilizumab and corticosteroids immediately available
Standard CRS/ICANS grading per ASTCT

Inclusion Criteria

1. Disease Characteristics

Histologically or cytologically confirmed small cell lung cancer.
Extensive-stage disease at study entry.
Relapsed or refractory after:
- ≥1 prior platinum-based regimen (must have received platinum/etoposide)
- Prior PD-1/PD-L1 therapy unless contraindicated or not available.
Measurable disease per RECIST v1.1.
Radiographic progression on or after most recent therapy.

2. Performance Status and Prognosis

ECOG performance status 0–1
(Consider allowing ECOG 2 in dose-expansion once safety is characterized.)
Estimated life expectancy ≥ 12 weeks.

3. Organ Function (within 7–14 days of first dose)

Hematologic

ANC ≥ 1.5 × 10⁹/L
(≥1.0 × 10⁹/L allowed if marrow involvement)
Platelets ≥ 100 × 10⁹/L
(≥75 × 10⁹/L if marrow involvement)
Hemoglobin ≥ 9.0 g/dL (transfusion allowed)

Hepatic

Total bilirubin ≤ 1.5 × ULN
(≤3 × ULN if Gilbert’s or liver metastases)
AST/ALT ≤ 3 × ULN
(≤5 × ULN if liver metastases)

Renal

Creatinine clearance ≥ 50 mL/min (Cockcroft-Gault)
OR serum creatinine ≤ 1.5 × ULN

4. CNS Disease (Balanced for Enrollability)

Treated brain metastases are allowed if:
- Definitively treated (radiation or surgery)
- Clinically stable ≥2 weeks
- Off steroids or on physiologic replacement only (≤10 mg prednisone equivalent)
Asymptomatic untreated brain metastases ≤2 cm may be allowed in dose-expansion only, provided:
- No mass effect
- No edema requiring steroids

(Important for enrollability in ES-SCLC while mitigating ICANS risk.)

5. CRS/ICANS Safety-Specific Inclusion

Baseline neurologic exam without clinically significant deficits.
No history of grade ≥3 immune-related neurologic toxicity from prior IO.
Oxygen saturation ≥ 92% on room air.
Adequate cardiac reserve:
- No symptomatic heart failure
- No MI within 6 months
- No unstable arrhythmias

6. Washout Periods

≥2 weeks from prior chemotherapy or radiation (≥4 weeks for nitrosoureas/mitomycin C).
≥4 weeks from prior investigational biologic agents.
Toxicities from prior therapy recovered to Grade ≤1 (except alopecia, stable neuropathy ≤Grade 2).

Exclusion Criteria

1. CNS / Neurologic Risk (ICANS Mitigation)

Active, untreated, or symptomatic brain metastases.
Leptomeningeal disease.
History of:
- Seizure disorder requiring anti-epileptics
- Stroke within 6 months
- Clinically significant CNS hemorrhage
Active autoimmune neurologic disease (e.g., MS, myasthenia gravis).
Baseline ≥ Grade 2 cognitive impairment.

2. CRS Risk Amplifiers

Active uncontrolled infection (including sepsis).
Known active hepatitis B, C with viremia.
HIV with detectable viral load.
Ongoing systemic immunosuppression:
- >10 mg prednisone equivalent daily within 7 days of first dose.
Active autoimmune disease requiring systemic therapy within past 2 years (replacement therapy allowed).

3. Cardiopulmonary Risk (CRS Hemodynamic Stress)

NYHA Class III or IV heart failure.
LVEF < 45–50% (if clinically indicated to assess).
Clinically significant pericardial effusion.
Baseline QTcF > 470 ms.
Significant baseline hypoxia requiring >2L supplemental O₂.
Uncontrolled COPD exacerbation or active pneumonitis.

4. Hematologic / Organ Exclusions

Platelets < 75 × 10⁹/L.
ANC < 1.0 × 10⁹/L.
AST/ALT > 5 × ULN without liver metastases.
Creatinine clearance < 40 mL/min.

5. Other Standard Exclusions

Second active malignancy requiring treatment.
Major surgery within 2 weeks.
Pregnancy or breastfeeding.
Live vaccines within 4 weeks.

Optional Risk Mitigation Measures (Protocol-Specified, Not Eligibility)

To further balance safety and enrollability without over-restricting:

Mandatory inpatient monitoring for:
Cycle 1 Day 1 and step-up doses
Baseline and serial ICE scoring
Baseline CRP and ferritin
Tocilizumab available within 2 hours
Pre-medication (e.g., dexamethasone) during priming doses
Exclude first-patient-in-human cohort from patients with:
Brain metastases
ECOG 2
Heavy tumor burden causing baseline hypoxia

Rationale for Key Decisions

Risk	Design Approach	Enrollability Impact
CRS	Exclude unstable cardiac/pulmonary disease; allow stable comorbidities	Preserves real-world population
ICANS	Allow treated/stable brain mets	Critical for ES-SCLC feasibility
Cytopenias	Allow marrow involvement with lower thresholds	Prevents over-exclusion
Steroids	Allow physiologic replacement	Avoids unnecessary exclusions
ECOG	0–1 initially	Expand to 2 once safety established

Optional Expansion Cohort Relaxations (After Dose Escalation)

Once RP2D safety is defined:
- Allow ECOG 2
- Allow asymptomatic untreated brain mets
- Lower ANC threshold to 1.0 × 10⁹/L universally
- Broaden CrCl to ≥40 mL/min

If helpful, I can next provide:

A Dose-Limiting Toxicity (DLT) definition framework tailored to CRS/ICANS,
A Cycle 1 hospitalization and monitoring schema, or
A risk-adapted eligibility strategy comparing “conservative FIH” vs “competitive landscape” approaches.

Class-effect liability to address	Why it constrains eligibility
Cytokine release syndrome (CRS) — common, mostly cycle-1, can be high-grade	Drives cycle-1 inpatient monitoring + exclude poor cardiac/pulmonary reserve and active infection.
Immune effector cell-associated neurotoxicity syndrome (ICANS) / neurotoxicity	Exclude active CNS mets / leptomeningeal / seizure disorder; baseline neuro exam.
Cytopenias (neutropenia, anemia, thrombocytopenia)	Set ANC/platelet/hemoglobin thresholds; CBC monitoring.
Hypogammaglobulinemia / infection risk from on-target B/neuroendocrine effects	Baseline TB/HBV/HCV screening; exclude active/latent untreated infection.
Tumor flare / pyrexia	Should be reflected in an exclusion, lab threshold, or monitoring requirement.

Eligibility-Criteria Authoring — agent trajectory for expert review

Query

Trajectory

Key Design Assumptions (Operational Context)

Inclusion Criteria

1. Disease Characteristics

2. Performance Status and Prognosis

3. Organ Function (within 7–14 days of first dose)

Hematologic

Hepatic

Renal

4. CNS Disease (Balanced for Enrollability)

5. CRS/ICANS Safety-Specific Inclusion

6. Washout Periods

Exclusion Criteria

1. CNS / Neurologic Risk (ICANS Mitigation)

2. CRS Risk Amplifiers

3. Cardiopulmonary Risk (CRS Hemodynamic Stress)

4. Hematologic / Organ Exclusions

5. Other Standard Exclusions

Optional Risk Mitigation Measures (Protocol-Specified, Not Eligibility)

Rationale for Key Decisions

Optional Expansion Cohort Relaxations (After Dose Escalation)

Final output

Key Design Assumptions (Operational Context)

Inclusion Criteria

1. Disease Characteristics

2. Performance Status and Prognosis

3. Organ Function (within 7–14 days of first dose)

Hematologic

Hepatic

Renal

4. CNS Disease (Balanced for Enrollability)

5. CRS/ICANS Safety-Specific Inclusion

6. Washout Periods

Exclusion Criteria

1. CNS / Neurologic Risk (ICANS Mitigation)

2. CRS Risk Amplifiers

3. Cardiopulmonary Risk (CRS Hemodynamic Stress)

4. Hematologic / Organ Exclusions

5. Other Standard Exclusions

Optional Risk Mitigation Measures (Protocol-Specified, Not Eligibility)

Rationale for Key Decisions

Optional Expansion Cohort Relaxations (After Dose Escalation)

Expert grading